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ACR = American College of Rheumatology response criteria; AOSD = adult-onset Still’s disease; AS = ankylosing spondylitis; BASDAI = Bath
Ankylosing Spondylitis Disease Activity Index; CRP = C-reactive protein; DMARD = disease-modifying antirheumatic drug; ESR = erythrocyte
sedimentation rate; Fc = crystallizable fragment; IL = interleukin; MTX = methotrexate; PASI = Psoriasis Area and Severity Index; PGA = physician’s
global assessment; PsA = psoriatic arthritis; RA = rheumatoid arthritis; TNF-α = tumor necrosis factor alpha.
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Introduction
Significant advances in recent years have improved the
understanding of the pathogenesis of rheumatoid arthritis
(RA). It is thought that TNF-α resides at the apex of an
inflammatory cytokine cascade that is responsible for the
pathophysiology of RA. The central role for TNF-α in RA is
supported by several findings. Secreted by cultured syn-
oviocytes, TNF-α is elevated in sera and synovial fluid of
RA patients [1–3]. In addition, anti-TNF-α antibodies have
been shown to prevent polyarthritic disease in two mouse
models [4,5].
The new appreciation of the importance of TNF-α in the
pathophysiology of RA has led to the clinical development
of a new class of targeted therapeutic agents. Etanercept
(Enbrel®; Immunex, Seattle, WA, USA) is a fusion protein
of the extracellular ligand-binding portion of the p75 TNF
receptor and the Fc portion of IgG1. Etanercept binds to
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Abstract
Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine that has been implicated in a variety of
rheumatic and inflammatory diseases. New understanding of the importance of TNF-α in the
pathophysiology of rheumatoid arthritis and Crohn’s disease led to the development of a new class of
targeted anti-TNF therapies. Anti-TNF-α agents including etanercept (a fusion protein of the p75 TNF
receptor and IgG1) and infliximab (a chimeric monoclonal antibody specific for TNF-α) have been
approved for the treatment of rheumatoid arthritis. In addition, infliximab has been approved in the
treatment of patients with active or fistulating Crohn’s disease. A new appreciation of the importance
of TNF-α in other rheumatic and inflammatory diseases has led to a broadening of the application of
anti-TNF agents. Both etanercept and infliximab have been used in open-label and randomized studies
in patients with psoriatic arthritis. Although larger randomized trials are needed to confirm early results,
both these anti-TNF-α agents, etanercept and infliximab, have demonstrated activity in improving the
signs and symptoms of psoriatic arthritis and psoriasis. Infliximab has also been shown to be effective
in patients with other rheumatic diseases, including ankylosing spondylitis, and may be effective in
adult-onset Still’s disease, polymyositis, and Behçet’s disease. Further investigations will fully elucidate
the role of infliximab in these and other rheumatic diseases.
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soluble TNF-α and lymphotoxin-α, thus blocking the acti-
vation of TNF receptors. Infliximab (Remicade®; Centocor,
Malvern, PA, USA) is a chimeric (human/mouse) antibody
that binds with high affinity and specificity to both the
soluble and membrane-bound forms of TNF-α. In addition,
infliximab also binds to TNF-α already engaged with the
TNF receptor. Infliximab thus neutralizes soluble and mem-
brane-bound TNF-α and can inhibit the activation of TNF
receptors before and after TNF-α engages with the receptor.
Both etanercept and infliximab have demonstrated efficacy
in reducing the signs and inflammatory symptoms of RA
and in inhibiting joint erosion in clinical trials [6–10]. In
addition, infliximab has been shown to significantly inhibit
joint space narrowing [10].
Etanercept and infliximab have both been approved for the
treatment of RA by the US Food and Drug Administration
and by the European Agency for the Evaluation of Medicinal
Products. In addition, infliximab has been approved for the
treatment of Crohn’s disease in patients with moderately to
severely active or fistulating disease [11,12]. Success in
the treatment of these inflammatory diseases with anti-TNF
agents has prompted the investigation of this therapeutic
modality in the treatment of other rheumatic diseases,
including psoriatic arthritis (PsA), ankylosing spondylitis
(AS), adult-onset Still’s disease (AOSD), and polymyositis.
Current diseases under investigation
The use of anti-TNF agents in the treatment of PsA, AS,
AOSD, and polymyositis has been based on evidence
suggesting that TNF plays a role in these inflammatory
rheumatic diseases. In the present article, the evidence of
activity of anti-TNF-α therapy in the treatment of these
diseases will be reviewed.
PsA and psoriasis
Psoriasis is reported to affect between 1 and 3% of adults
in the United States, and PsA occurs in approximately
6–20% of psoriasis patients [13]. PsA is an inflammatory
arthropathy that may present in a symmetric or an asym-
metric polyarticular form, with or without onycholysis. The
current therapeutic approaches for PsA are similar to
those for RA and include nonsteroidal anti-inflammatory
drugs, disease-modifying antirheumatic drugs (DMARDs),
and immunosuppressive agents. Only two DMARDs,
methotrexate (MTX) [14] and sulfasalazine [15], have
demonstrated efficacy in the treatment of PsA. These
agents are, however, associated with significant adverse
events, and many patients do not respond to these treat-
ments. Other therapeutic options are therefore needed.
TNF-α has been linked to the pathogenesis of PsA and
psoriasis because of its ability to upregulate adhesion mol-
ecules and to trigger an inflammatory cytokine cascade.
TNF-α induces the expression of intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1, both of
which are involved in lymphocyte trafficking to inflamma-
tory lesions [16]. Circulating T lymphocytes and
macrophages isolated from PsA patients produce an
increased amount of TNF-α compared with macrophages
isolated from healthy controls [17]. Furthermore, the levels
of TNF-α are elevated in the synovial fluid [18,19] and skin
lesions [20,21] in PsA patients, with TNF-α levels corre-
lated with disease activity [22,23].
Several open-label studies have investigated the use of
anti-TNF-α agents in the treatment of PsA and psoriasis
[24–28]. In a single-center, open-label report on the treat-
ment of spondyloarthopathies, Van den Bosch et al. [24]
reported that nine PsA patients treated with 5 mg/kg
infliximab (weeks 0, 2, and 6) experienced significant
improvement in physician’s global assessment (PGA)
scores, erythrocyte sedimentation rates (ESRs), and
C-reactive protein (CRP) levels. Of these nine patients,
eight had psoriasis at baseline. After 12 weeks of
infliximab treatment, baseline Psoriasis Area and Severity
Index (PASI) scores were significantly decreased
(improved). The clinical improvements in all PsA and
psoriasis disease manifestations were maintained over a
1-year follow-up period [25].
In another open-label study, eight out of 10 heavily pre-
treated PsA patients experienced improvements in Health
Assessment Questionnaire scores and PGA scores after
12 months of treatment with 25 mg etanercept (subcuta-
neously, twice per week). All four patients in this trial with
active psoriasis had significant improvement in their psoriatic
lesions, including complete resolution in three patients [26].
In our open-label experience, infliximab treatment was effi-
cacious and safe in both PsA and psoriasis [27,28]. With
infliximab treatment (5 mg/kg at weeks 0, 2, and 6), all
10 patients in our study achieved 20% improvement in
arthritis per the American College of Rheumatology
response criteria (ACR) by week 2. After 10 weeks of
treatment, eight patients achieved 70% improvement per
the ACR, with six patients maintaining this improvement
after 54 weeks. In addition, magnetic resonance imaging
showed an 82% reduction in inflammation in peripheral
joints, and mean PASI scores were reduced by 71% at
week 10. After 10 weeks of infliximab therapy, six patients
experienced nearly complete clearing of erythematous
psoriasis plaques (Fig. 1). Furthermore, histopathologic
analysis of psoriatic plaques showed a reduction in epi-
dermal hyperplasia and inflammation by week 10
(Fig. 2).This reduction in hyperplasia was associated with
a decrease in plaque size and was evident from the near-
normal epidermal structure after infliximab treatment.
The use of anti-TNF agents in treating PsA and psoriasis
has also been investigated in randomized, double-blinded,S36
Arthritis Research    Vol 4 Suppl 2 Kalden
placebo-controlled studies. Mease et al. [29] reported that
87% of patients receiving 25 mg etanercept (subcuta-
neously, twice per week) achieved Ps ACR response cri-
teria, compared with 23% of placebo patients
(P < 0.0001). Seventy-three per cent of etanercept-
treated patients achieved 20% improvement of the ACR,
compared with 13% of placebo-treated patients
(P < 0.0001). Of 19 patients in each treatment group with
active psoriasis, the median improvement in PASI scores
was significantly higher in etanercept-treated patients than
that in placebo-treated patients. Of the psoriasis patients
treated with etanercept, 26% achieved a 75% improve-
ment, compared with no patients treated with placebo. In
an open-label extension study, etanercept continued to
effectively reduce clinical signs and symptoms of PsA and
psoriasis for up to 36 weeks [30].
Chaudhari et al. [31] recently described the first reported
placebo-controlled, randomized study designed to investi-
gate the efficacy of an anti-TNF agent in psoriasis patients.
In this study, 30 patients were randomized to receive
5 mg/kg or 10 mg/kg infliximab or placebo. Nine of 11
(82%) patients treated with 5 mg/kg infliximab achieved
good, excellent, or clear ratings on PGA, compared with
only two of 11 (18%) patients receiving placebo
(P = 0.0089). In addition, 10 of 11 (91%) patients treated
with 10 mg/kg infliximab achieved these ratings
(P = 0.0019, compared with placebo). A significantly higher
proportion (P = 0.0089, 5 mg/kg infliximab versus placebo;
P = 0.03, 10 mg/kg infliximab versus placebo) of patients
treated with infliximab obtained a 75% improvement in PASI
scores compared with those receiving placebo. The results
of these studies suggest that TNF-α plays a pivotal role in
the pathogenesis of PsA and psoriasis. In addition, anti-
TNF-α therapy offers patients with PsA and psoriasis a new
therapeutic option for the control of their disease.
Ankylosing spondylitis
AS is an inflammatory arthropathy that preferentially
affects the axial skeleton, usually manifesting in the sacro-
iliac joints and then ascending to involve the axial skeleton
[32,33]. Treatment for AS includes nonsteroidal anti-
inflammatory drugs and sulfasalazine, the only DMARD
that shows activity, albeit limited, in the disease [34].
Only limited evidence exists to support a role for TNF-α in
the pathophysiology of AS. Braun et al. [35] showed that
TNF-α mRNA and protein were present in inflamed
sacroiliac joints of AS patients. Lange et al. [36] recently
reported significantly increased TNF-α plasma levels in AS
patients, with a positive correlation between TNF-α
plasma levels and the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI). In addition, the strong
link between AS and inflammatory bowel disease (where
20–60% of spondyloarthropathy patients have gastro-
intestinal lesions resembling those in Crohn’s disease) pro-
vides circumstantial evidence for a role of TNF-α in AS [37].
Despite a general lack of evidence for a role of TNF-α in
the pathophysiology of AS, clinicians are beginning to
investigate the use of anti-TNF therapies in this inflamma-
tory disease. In an open-label study, 11 patients with AS
of short duration were treated with 5 mg/kg infliximab at
weeks 0, 2, and 6 [38]. Improvements in activity, in func-
tion, and in pain scores of ≥50% were reported in nine of
10 eligible patients. The median CRP level decreased to
normal levels and the median improvement in BASDAI
scores after 4 weeks was 70%.
Figure 1
Psoriasis plaques on patient skin. Depicted is a representative set of
patient plaques (a) before and (b) 10 weeks after infliximab treatment.
Note the characteristic sharply circumscribed erythematous psoriasis
plaque covered by silvery scales prior to infliximab therapy.
Figure 2
Histopathologic psoriasis plaques. Epidermal and dermal
characteristics of psoriasis plaques from a representative patient 
(a) before and (b) 10 weeks after infliximab treatment.S37
In another open-label study of patients with different sub-
types of spondyloarthropathy, 10 AS patients treated with
5 mg/kg infliximab every 14 weeks achieved significant
improvements in morning stiffness, tender and swollen
joint counts, ESR, CRP, and BASDAI, Bath Ankylosing
Spondylitis Functional Index, and Bath Ankylosing
Spondylitis Metrology Index scores. Improvement in ESR
and CRP was significant at day 3 after infliximab treatment
and was maintained to day 84. Improvements in the other
endpoints were significant at day 14 and were also main-
tained to day 84. The significant improvements in the
global, peripheral, and axial disease manifestations were
maintained over a 1-year follow-up period [25].
In a larger open-label study, 48 patients with severe AS
were treated with infliximab. Significant improvements in
mean disease activity, global pain, BASDAI, Bath Ankylos-
ing Spondylitis Functional Index scores, and CRP levels
were observed at week 8 [39].
The results of the aforementioned open-label studies were
recently confirmed in a double-blind, placebo-controlled,
phase III clinical trial [40]. A total of 70 patients with active
AS were enrolled in the study and were randomized to
receive placebo (n = 35) or to receive 5 mg/kg infliximab
(n = 35) at weeks 0, 2, and 6, and then every 6 weeks
until week 48. At the time of the report, 66 patients had
completed 3 months of treatment. A 50% improvement in
BASDAI was achieved by 53% of patients treated with
infliximab, compared with 9% of patients treated with
placebo (P < 0.01).
Adult-onset Still’s disease
AOSD is a rare systemic inflammatory disorder of
unknown etiology. Clinical symptoms of this disease are
high spiking fever, arthritis, transient cutaneous rashes,
and sore throat [41]. AOSD is considered identical to the
systemic form of juvenile RA [42]. A markedly elevated
serum ferritin correlates with disease activity [43,44], and
several inflammatory cytokines (e.g. IL-18) are elevated in
these patients [45–47]. Furthermore, Hoshino et al. [46]
reported elevated serum levels of TNF-α in AOSD
patients. Kawashima et al. [47] recently demonstrated that
the proinflammatory cytokine IL-18 is markedly elevated in
the serum of AOSD patients during the acute phase of
their disease. Because it has been shown that TNF-α
induces the expression of IL-18 in synovial tissues [48],
anti-TNF agents may lead to a reduction of IL-18 in AOSD
patients. Bombardieri et al. [49] recently demonstrated
that infliximab reduced IL-18 serum levels in RA patients.
Studies to determine whether infliximab also reduces
IL-18 serum levels in AOSD are therefore warranted.
The current treatment for AOSD is mostly limited to the
use of nonsteroidal anti-inflammatory drugs and, in severe
cases, of prednisone. However, many patients become
dependent on high-dose prednisone or are refractory to
corticosteroid treatment. In a retrospective analysis of 26
AOSD patients, MTX was an effective second-line treatment
for patients who had not responded to prednisone [50].
However, controlled studies of MTX and other DMARDs in
the treatment of AOSD have not been performed.
Interest in using anti-TNF therapy in treating AOSD
increased following a report that infliximab was effective in
suppressing fever and acute phase response in a patient
with juvenile chronic arthritis [51]. Furthermore, thalido-
mide, a known inhibitor of TNF-α, was reported to
markedly improve clinical symptoms in a patient with treat-
ment-resistant AOSD [52]. Systematic investigation of
anti-TNF-α therapy in AOSD is in its early stages. An
open-label trial evaluated the efficacy of infliximab in the
treatment of AOSD refractory to conventional therapy
[53]. Three patients with chronic and active AOSD who
were unresponsive to corticosteroids and MTX were
administered 3 mg/kg infliximab at weeks 0, 2, and 6, and
then every 8 weeks thereafter, along with concomitant
15 mg/week MTX. Disease activity had improved in all
three patients at 50 weeks of follow-up, and two patients
experienced reductions in ESR, CRP, prednisone dose,
and PGA score.
In a recent pilot study conducted at our institution, six
AOSD patients treated with infliximab reported marked
improvements in the clinical signs and symptoms of
AOSD [54]. Patients were treated with 5 mg/kg infliximab
at weeks 0, 2, and 6, and thereafter at intervals of
6–8 weeks. Fever, arthralgias, myalgias, splenomegaly,
and rash were resolved in all six patients within the first
three courses of infliximab treatment. A summary of the
serologic and disease activity parameters is presented in
Table 1. Although the results of these open-label trials
need to be confirmed in randomized, placebo-controlled
studies, the preliminary results suggest infliximab is effec-
tive in managing relapse in refractory AOSD patients.
Polymyositis
Polymyositis is an idiopathic inflammatory myopathy that is
characterized by proximal muscle weakness, skeletal
muscle inflammation and damage, and elevated serum
levels of muscle-derived proteins such as creatinine
kinase. Polymyositis is associated with lymphocyte inva-
sion of muscle fibers, predominantly cytotoxic CD8+ T lym-
phocytes, which leads to muscle fiber necrosis,
degeneration, and fibrosis. The current first-line therapy for
polymyositis is prednisone [55]. However, many patients
only achieve partial response or do not respond at all to
high-dose corticosteroids. Because early recognition and
treatment of polymyositis is critical to prevent irreversible
muscle damage, second-line therapies such as MTX or
azathioprine should be administered to patients who fail
corticosteroid treatment [55].
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Tateyama et al. [56] demonstrated, using monoclonal anti-
bodies to TNF-α, that TNF-α-positive macrophages and
lymphocytes invade the endomysium in the muscles of
polymyositis patients. In addition, there was a correlation
between TNF-α levels in the endomysium and muscle fiber
atrophy. Kuru et al. [57] also demonstrated infiltration of
TNF-α-positive CD8+ lymphocytes and macrophages into
the muscle fibers of polymyositis patients.
The apparent involvement of cytokine-producing T lympho-
cytes in polymyositis initiated interest in treating these
patients with anti-TNF agents. There have been no pub-
lished accounts of the efficacy of anti-TNF therapy in
polymyositis, but a number of case studies have been pre-
sented. We recently treated a patient with polymyositis
refractory to immunosuppressive regimens with 4 mg/kg
infliximab every 6 weeks and concomitant MTX therapy.
This patient showed a significant response on infliximab
treatment, including a significant improvement in mobility.
The skeletal muscle-specific enzymes returned to normal
serum levels, indicating a substantial reduction in inflam-
mation. Although this is a single case study, it suggests
that anti-TNF-α therapy may be a viable treatment alterna-
tive for patients with refractory polymyositis. Further
studies to fully investigate the potential for anti-TNF-α
therapy in treating polymyositis are warranted.
Behçet’s disease
Behçet’s disease is a chronic autoimmune disorder charac-
terized by systemic vasculitis. This disease is associated
with mucocutaneous, ocular, articular, vascular, gastroin-
testinal, and central nervous system manifestations.
Approximately 70% of patients experience relapsing ocular
inflammation that can lead to blindness [58]. The etiology
of Behçet’s disease is unknown; however, some evidence
suggests that increased levels of TNF and soluble TNF
receptors are associated with active disease [59–61].
Interestingly, thalidomide, which has been used success-
fully in the treatment of Behcet’s disease, inhibits TNF-α by
accelerating the degradation of TNF-α mRNA [62]. Other
anti-TNF therapies may therefore benefit these patients.
Anti-TNF therapy has recently been used for the treatment
of patients with Behçet’s disease. Travis et al. [63]
reported the successful use of infliximab in two patients
with Behçet’s disease with rare gastrointestinal ulcera-
tions. Within 10 days of infliximab treatment, the ulcers
had healed and all extraintestinal manifestations had
resolved. Furthermore, five patients with relapsing panu-
veitis were successfully treated with infliximab. Remission
of ocular inflammation was evident within the first
24 hours, and complete suppression was observed within
7 days of infliximab therapy [64]. The rapid and effective
response of this handful of patients with Behçet’s disease
to infliximab clearly warrants further studies of the use of
anti-TNF therapy in treating this disease.
Conclusions
Anti-TNF-α therapy is currently approved for the treatment
of RA (infliximab in combination with MTX, and etanercept)
and of Crohn’s disease (infliximab). This brief summary of
study data supports a role for anti-TNF therapy in the treat-
ment of PsA, psoriasis, AS, AOSD, polymyositis, and
Behçet’s disease. Success in the treatment of these
inflammatory disorders suggests that anti-TNF therapy
may also be effective in treating other inflammatory dis-
eases, including ulcerative colitis, uveitis, and Felty’s syn-
drome. Future investigations will determine the breadth of
application of anti-TNF therapy in the treatment of autoim-
mune and inflammatory disorders.
Note added in proof
In January 2002, etanercept was awarded an additional
indication by the US Food and Drug Administration.
Etanercept was approved as monotherapy or in combina-
tion with methotrexate for reducing the signs and symp-
toms of psoriatic arthritis.
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